Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McDonald's Corp (MCD) vs Smith & Nephew plc (SNN) Price & Performance

McDonald's CorpTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

McDonald's Corp vs Smith & Nephew plc — how do they compare? McDonald's Corp trades at $273.95 (market cap $193.70B), while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: McDonald's Corp is far larger — about 15.5× Smith & Nephew plc's market cap, and McDonald's Corp pays the higher dividend (2.72%). Which is the better fit depends on your goals.

MCDSNN
Market Cap
$193.70B$12.50B
Volume
2,230,036
Sector
Consumer CyclicalHealth
52-Week High
$341.06$38.70
52-Week Low
$262.80$28.73
Enterprise Value
$247.47B$15.53B
Dividend Yield
2.72%2.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McDonald's Corp

McDonald's (MCD) trades at $274.15, down slightly by 0.12% on the day, with technical indicators showing a neutral overall signal. The company demonstrates strong fundamentals with consistent revenue growth, reaching $26.89 billion in 2025, and robust profitability with a 31.72% net income margin. Recent earnings have consistently beaten expectations, and the company has announced a new global growth strategy focused on automation and menu innovation to drive future performance.

The outlook for MCD is positive, supported by strong analyst consensus with a $322.45 price target implying significant upside. Key opportunities include the successful execution of its new growth plan and its defensive qualities in a challenging economy. Primary risks involve inflationary pressures on franchisee margins and intense competition in the quick-service restaurant sector.

Smith & Nephew plc

SNN trades at $30.11, up 1.41% in the last session. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 revenue growth of 1.6% but cut its full-year outlook to 4% from 6% due to weakness in U.S. Orthopaedics and Advanced Wound Bioactives (MarketBeat, 2026-08-09). Recent product launches include the LYNX COBLATION Wand and CORI XT robotics platform, supporting innovation in medical technology.

The outlook is mixed: strong profitability margins and recent earnings beats offer support, but lowered guidance and bearish technicals pose near-term headwinds. Risks include execution challenges in key markets, while analyst consensus leans Hold, reflecting cautious optimism amid growth uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About McDonald's Corp

McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.

Read more on MCD

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN